Optum UK acquired by TPG
Context
TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority. The sale process, managed by Bank of America, attracted significant interest from top-tier private equity firms, including Blackstone, reflecting the asset’s status as a high-quality infrastructure-like software provider. The strategic rationale for TPG is a clear "buy-and-build" play, as the firm intends to explore a merger between Optum UK and Nextech, its US-based electronic medical record software provider. Such a combination would create a transatlantic leader in healthcare IT, allowing for the cross-pollination of software features and a broader geographical footprint. For UnitedHealth, the divestment is viewed as a strategic move to optimize its portfolio and improve group valuation by offloading a business that, while dominant in its local market, faced significant regulatory scrutiny regarding vertical integration. The deal is expected to close in early 2026, subject to final negotiations and potential updated reviews by UK health and competition authorities, given the critical nature of the EPR systems provided to the NHS.
The acquisition of Optum UK is part of the growth strategy of TPG, which already has several external growth operations under its belt, notably A-Gas in 2023.
Optum UK, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of Above 20x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Optum UK, primarily comprising the operations of EMIS Group, is the leading provider of healthcare software and electronic patient record (EPR) systems in the United Kingdom. The company’s core business model focuses on supplying mission-critical technology infrastructure to the majority of Britain’s general practitioners (GPs), as well as community pharmacies and hospital departments. Its value proposition centers on the seamless management of clinical data, enabling healthcare professionals to access real-time patient information, streamline administrative workflows, and improve diagnostic accuracy. The group’s strategy is built on high levels of recurring revenue through long-term contracts with the National Health Service (NHS) and related healthcare providers. By acting as the digital backbone of primary care in the UK, Optum UK plays a vital role in the national healthcare ecosystem, facilitating the integration of patient care across different clinical settings and supporting the digital transformation of public health services through advanced data analytics and interoperable software solutions.
Ent. Value
£1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
4x–10x
EV / EBITDA
Above 20x
EV / EBIT
[members only]
Historical Financials (GBP)
Other operations with TPG
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2023 | TPG | A-GAS | UNITED KINGDOM | Hazardous Waste |
| 07/2022 | TPG | DOC GENERICI | ITALY | Generics / Labs |
| 04/2021 | TPG | THE MADE GROUP | AUSTRALIA | Dairy |
| 11/2014 | TPG | PREZZO | UNITED KINGDOM | Restaurants / Chains |
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2026 | THERMO FISHER SCIENTIFIC | CLARIO HOLDINGS | UNITED STATES | CRO / Clinical Trials |
| 03/2026 | RADNET | GLEAMER | FRANCE | Health Tech |
| 01/2026 | PERMIRA | CARNE GROUP | IRELAND | Healthcare Services |
| 01/2026 | ANTIN INFRASTRUCTURE | EMSERE | NETHERLANDS | CRO / Clinical Trials |
| 01/2026 | SAGARD | QUIPMENT | FRANCE | Healthcare Services |
| 12/2025 | PHARMA EQUITY GROUP | OTIOM | DENMARK | Health Tech |
| 11/2025 | EURAZEO | EXCELYA | FRANCE | CRO / Clinical Trials |
| 11/2025 | ASKER HEALTHCARE GROUP | FINMED GROUP | FRANCE | Hospital Logistics |
| 10/2025 | EVOLEM | APPERTON | FRANCE | Sterilization & Hygiene |
| 05/2025 | FIVE ARROWS | HUBLO | FRANCE | Health Tech |
REFERENCES
Valuation range: EV £1–10bn
Revenue range: £100–200M
EBITDA range: £50–100M
EV/Revenue range: 4x - 10x
EV/EBITDA range: Above 20x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Optum UK by TPG are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: optum uk
FAQ
What transaction does this page cover?
How was the acquisition of Optum UK by TPG valued, and what multiples were paid?
What were Optum UK’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?